Skip to main content

United States News All stories

Every story in this section, newest first — page 160 of 373.

Grafa
Retail

J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook

The J.M. Smucker Company (NYSE:SJM) reported a 20% increase in fourth-quarter adjusted earnings per share, driven by favorable pricing actions and portfolio management, while issuing a forward-looking forecast that projects a modest revenue contraction for the upcoming fiscal year.

Read more: J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook
Grafa
Retail

Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance

Designer Brands (NYSE:DBI) reported a slight expansion in its first-quarter top-line revenue, driven by strong growth within its wholesale division that helped offset softening demand across its core brick-and-mortar storefront network.

Read more: Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance
Grafa
Retail

Nathan’s Famous revenue rises to $162M as beef costs pinch profits

Nathan’s Famous (NASDAQ:NATH) reported higher top-line revenue for fiscal year 2026, driven by growth in its foodservice and franchise segments, even as surging input costs chipped away at overall profit margins ahead of its planned private ownership transition.

Read more: Nathan’s Famous revenue rises to $162M as beef costs pinch profits
Grafa
Technology

Baidu added to Pentagon’s Chinese military list, rejects designation

Baidu (NASDAQ:BIDU) confirmed that the U.S. Department of Defense has included the company on its updated list of "Chinese military companies," a classification the internet search and artificial intelligence giant quickly pushed back against as entirely unjustified.

Read more: Baidu added to Pentagon’s Chinese military list, rejects designation
Grafa

PureTech's Seaport advancing anxiety drug to Phase 2 on positive trial data

PureTech Health reported that its founded entity, Seaport Therapeutics (NASDAQ:SPTX), achieved positive clinical results from the multiple-ascending dose portion of its Phase 1 proof-of-concept trial evaluating its lead anti-anxiety candidate, GlyphAgo.

Read more: PureTech's Seaport advancing anxiety drug to Phase 2 on positive trial data